Ellinghorst IR compiles independent consensus forecasts of UCB based on the financial estimates of various analysts covering UCB.

In order to provide meaningful data only regularly updated or reiterated estimates are included in the consensus. The tables below are based on the estimates of over 15 different brokers. See the list of analysts and their contact details here

If you wish to be informed whenever we have updated consensus, simply send an e-mail to This email address is being protected from spambots. You need JavaScript enabled to view it. quoting "consensus email alert" as subject.  

 ucb

UCB FY Consensus Product Sales Estimates (Average)

In € million 2019a 2020e 2021e 2022e  2023e  2024e  2025e
Core Products              
Cimzia 1,712 1,837 1,924 1,974 1,956 1,821 1,552
Vimpat 1,322 1,455 1,565 1,392 862 659 528
Keppra  770 738 696 632 581 539 505
Briviact 221 295 364 429 490 544 589
Neupro 319 300 257 203 167 142 122
6 Potential new Product Launches*
(global sales, non-risk adj.)
             
Evenity (romosozumab)   388  536  670  809 932  1,017
Midazolam nasal spray   19 40  59  77  90  99
Bimekizumab   67  230  440  639   907
Rozanolixizumab (Rozimab/Roza)   41  120 263  433 
Padsevonil   25 89  176  273
Anti-Tau    0  0  0 84 196

  *until 2025

UCB FY Consensus Earnings Estimates (Average)

In € million 2019a 2020e 2021e 2022e  2023e
Net Sales  4,680 4,995 5,301 5,379 5,197
Revenue  4,913 5,197 5,503 5,583 5,401
Recurring EBIT 1,118  1,112 1,294 1,429 1,357
Recurring EBITDA 1,431  1,448 1,632 1,766 1,702
Net Profit*  792 818 982 1,107 1,056
Core EPS (€) 5.20  5.02 5.89 6.54 6.30

*attributable to UCB shareholders  

UCB FY Consensus Product Sales Estimates (Median)

In € million 2019a 2020e 2021e 2022e  2023e  2024e  2025e
Core Products              
Cimzia 1,712 1,841 1,920 1,986 1,945 1,808 1,554
Vimpat 1,322 1,434 1,542 1,411 918 717 540
Keppra 770 740 683 625 579 529 486
Briviact 221 299 369 429 491 546 586
Neupro 319 308 258 202 172 144 120
6 Potential new Product Launches*
(global sales, non-risk adj.)
             
Evenity (romosozumab)   405 525 662 806 914 1,000 
Midazolam nasal spray   18 40  60  80  100 112
Bimekizumab   67  210 401  621  809 
Rozanolixizumab (Rozimab/Roza)   30  100 243  416
Padsevonil   19 80  182 274
Anti-Tau    0 108  245 

 *until 2025

UCB FY Consensus Earnings Estimates (Median)

In € million 2019a 2020e 2021e 2022e  2023e
Net Sales  4,680 4,994 5,266  5,353  5,207
Revenue  4,913 5,216 5,495 5,564 5,489
Recurring EBIT 1,118  1,112 1,307 1,451 1,429
Recurring EBITDA  1,431 1,443 1,639 1,748 1,729
Net Profit*  792  795 935 1,080 1,069
Core EPS (€) 5.20 4.99 5.88 6.53
6.53

*attributable to UCB shareholders

Downloads:
UCB FY 2019 Consensus (Excel)
UCB FY P&L Consensus (PDF)
UCB FY Product Sales Consensus (PDF)

Last updated: 6 March, 2020



Check out UCB's new IR Apps: 

App Apple Store

App Google Play

 

Disclaimer:

This document has been compiled by Ellinghorst IR Ltd. for information purposes only and is not intended to constitute investment advice. It is based on estimates and forecasts of various analysts regarding revenues, earnings and business developments of the relevant company. Such estimates and forecasts cannot be independently verified by reason of the subjective character. Ellinghorst IR Ltd. gives no guarantee, representation or warranty and is not responsible or liable as to its accuracy and completeness. Ellinghorst IR Ltd. has not commented and will not comment on any of the individual financial forecasts used to generate the information contained herein.